Trial Profile

A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Sabatolimab (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms STIMULUS-AML1
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

08 Apr 2025 According to clinicaltrial.gov, the study was terminated because results from 2 trials in the program were negative (including the main trial) and Novartis decided to terminate the program all together.
08 Apr 2025 Status changed from completed to discontinued.
03 Mar 2025 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com